Physician profile
Chad Pedersen
NPI 1881857019
$73,911.81
in general payments reported to CMS, 2019-2025
31 companies · $7,131 in 2025
The $7,131 reported for 2025 was more than what 78% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $341 · 2021: $687 · 2022: $1,417 · 2023: $32K · 2024: $32K · 2025: $7,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Consulting Fee: $13K · Travel and Lodging: $10K · Food and Beverage: $6,265 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,242.50 |
| Consulting Fee | $13,345.00 |
| Travel and Lodging | $10,367.74 |
| Food and Beverage | $6,265.21 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $60,156.80 | 2023-2024 | Bavencio |
| Syndax Pharmaceuticals, INC. | $6,378.93 | 2025 | Revuforj |
| Astrazeneca Pharmaceuticals Lp | $1,253.79 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,216.72 | 2019-2023 | Opdivo, Reblozyl |
| Exelixis INC. | $919.42 | 2020-2025 | Cabometyx |
| Tempus Ai, INC | $528.13 | 2024-2025 | Xt Cdx |
| Myriad Genetic Laboratories, INC. | $416.86 | 2023 | Myrisk |
| Cti Biopharma Corp. | $392.35 | 2023 | Vonjo |
| Amgen INC. | $305.83 | 2019-2025 | Imdelltra (Amg757), Imdelltra (Amg 757), Kyprolis |
| Adaptive Biotechnologies Corporation | $304.62 | 2023-2025 | Clonoseq |
| Janssen Biotech, INC. | $250.00 | 2023-2024 | Erleada, Akeega |
| Regeneron Healthcare Solutions, INC. | $245.97 | 2022-2023 | Libtayo |
| Genzyme Corporation | $239.92 | 2021-2023 | |
| Blueprint Medicines Corporation | $153.72 | 2022 | |
| Glaxosmithkline, LLC. | $150.37 | 2024-2025 | Ojjaara, Zejula, Jemperli |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.00 | 2024 | |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Agios Pharmaceuticals, INC. | $125.00 | 2023 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $114.07 | 2023-2025 | Ultomiris |
| Incyte Corporation | $99.95 | 2021 | |
| Daiichi Sankyo INC. | $79.29 | 2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $66.25 | 2022-2025 | Fruzaqla |
| Novocure INC. | $60.89 | 2024 | Optune |
| Pfizer INC. | $44.57 | 2019 | |
| Gilead Sciences, INC. | $36.65 | 2021 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Stemline Therapeutics INC. | $19.23 | 2025 | Orserdu |
| Merck Sharp & Dohme LLC | $19.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2024 | |
| Seagen INC. | $17.25 | 2021 | |
| Lilly USA, LLC | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Pedersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.